A collaboration developing a new Web site to help medical practitioners compare electronic health records systems was announced today by its founding partners, the American College of Physicians and C

Spring is here and allergy flare-ups are often attributed to the allergens outside your front door.

Every spring and summer, millions of Americans dread the trip to the park, the playground, or participating in any of the myriad activities that trigger outdoor allergy symptoms.

Women living in the northeastern United States are more likely to develop rheumatoid arthritis, suggesting a link between the autoimmune disease and vitamin D deficiency, says a new study led by a Bos

Allergy

Dyax Corp. announced the publication of a first-ever comprehensive examination of the economic burden associated with the treatment of acute attacks and chronic management of hereditary angioedema (HAE). The results, published today in the Annals of Allergy, Asthma, and Immunology, bring to light the substantial direct and indirect medical costs of the disease on patients, payers and society. The economic study is one component of a larger survey-based Burden of Illness (BOI) study which assessed both the economic and humanistic burden of HAE.

"Gilead Sciences Inc. may learn this year whether its drugs for treating HIV can also stop people from catching the virus in the first place," Bloomberg writes in a piece that examines the potential benefits and drawbacks to using low-doses of HIV/AIDS medications to reduce a person's risk of becoming infected with HIV. According to the news service, the initial results of 10 trials including more than 20,000 people could be available as early as July.

Soligenix, Inc., a late-stage biopharmaceutical company, today announced its financial results for 2009.

The Minnesota Optometric Association offers advice for the thousands around the state who suffer from the itchy, watery eye symptoms associated with seasonal Spring allergens. The culprits exist indoors and out: pollen, mold, dust mites and pet dander.

Ardea Biosciences, Inc. today announced positive, preliminary, top-line results from its Phase 2b monotherapy study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout. In this 28-day, randomized, double-blind, placebo-controlled, dose-escalation study, 123 gout patients with hyperuricemia (serum urate levels greater than or equal to 8 mg/dL) received 200 mg once-daily (qd) RDEA594, 400 mg qd RDEA594, 600 mg qd RDEA594 or matching placebo.